title: Treatment with clodronate in patients with hypercalcemia secondary to malignancy.
abstract: Dichloromethylene bisphosphonate (clodronate, Cl2MDP) is a synthetic analogue to pyrophosphate, which inhibits increased bone resorption. This drug was given to 12 patients with hypercalcemia secondary to advanced malignant disease. Clodronate in a daily dose of 1.6 to 3.2 g generally caused a return of the serum calcium values to normal within 5-10 days with a concomitant improvement of symptoms related to the hypercalcemia. Side effects were few. Thus, clodronate appears to be a valuable adjunct for the medical management of patients with malignancy-associated hypercalcemia.
authors.affiliation: Department of Internal Medicine, Gävle County Hospital, Uppsala, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Lind
authors.forename: B
authors.initials: B
authors.lastname: Wengle
authors.forename: S
authors.initials: S
authors.lastname: Ljunghall
mesh_terms: D000328:Adult; D000368:Aged; D004002:Clodronic Acid / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*
chemical_list: D004164:Diphosphonates; D004002:Clodronic Acid